Department of Medicine 5 – Haematology and Oncology

A novel immunoregulatory function of beta-2-microglobulin as a promoter of myeloid derived suppressor cell induction (2019) Bruns H, Jitschin S, Gamali S, Saul D, Böttcher M, Mackensen A, Jitschin R, Mougiakakos D Journal article Clinical Characteristics and Outcome in IDH1/2 Mutant AML Patients - Analysis of 3898 Newly Diagnosed Patients with Acute Myeloid Leukemia (2018) Middeke JM, Rollig C, Kramer M, Kramer A, Bochtler T, Scholl S, Hochhaus A, et al. Conference contribution Serial Biomarker Monitoring Early after HCT Identifies Different Risks for Relapse and Graft-Vs-Host Disease (2018) Aziz MD, Shah J, Kapoor U, Dimopoulos CN, Ayuk FA, Hogan WJ, Schreiner E, et al. Conference contribution EZH2 Mutations and Impact on Clinical Outcome Analyzed in 1604 Patients with Acute Myeloid Leukemia (2018) Stasik S, Middeke JM, Kraemer M, Rollig C, Kramer A, Scholl S, Hochhaus A, et al. Conference contribution Comorbidities Are Frequent in Older Patients with De Novo Acute Lymphoblastic Leukemia (ALL) and Correlate with Induction Mortality: Analysis of More Than 1200 Patients from GMALL Data Bases (2018) Wermann WK, Viardot A, Kayser S, Alakel N, Elmaagacli A, Faul C, Fiedler W, et al. Conference contribution Nilotinib Vs Nilotinib Plus Pegylated Interferon-alpha2b Induction and Nilotinib or Pegylated Interferon-alpha2b Maintenance Therapy for Newly Diagnosed BCR-ABL plus Chronic Myeloid Leukemia Patients in Chronic Phase: Interim Analysis of the Tiger (CML V)-Study (2018) Hochhaus A, Saussele S, Baerlocher GM, Bruemmendorf TH, Burchert A, La Rosee P, Hasford J, et al. Conference contribution MOR202 with Low-Dose Dexamethasone (Dex) or Pomalidomide/Dex or Lenalidomide/Dex in Relapsed or Refractory Multiple Myeloma (RRMM): Primary Analysis of a Phase I/IIa, Multicenter, Dose-Escalation Study (2018) Raab MS, Chatterjee M, Goldschmidt H, Agis H, Blau I, Einsele H, Engelhardt M, et al. Conference contribution Prolyl Hydroxylase 3 (Phd3) Is a Therapeutic Target in Isocitrate Dehydrogenase 1 (IDH1) Mutated Acute Myeloid Leukemia (2018) Chaturvedi A, Cruz MMA, Goparaju R, Gabdoulline R, Schottmann R, Goerlich K, Kloos A, et al. Conference contribution DNA Damage-Response Pathway in Lymphoma Determines Interactions with Macrophages By Altered PD-Li Expression and Fxosome Formation (2018) Vorholt D, Izquierdo-Alvarez E, Sackey B, Schmitz J, Nickel N, Blakemore S, Knittel G, et al. Conference contribution Myc-Driven, Primary Mouse Lymphoma Expressing Human CD22 Are Highly Infiltrated By Syngeneic Immune Cells and Provide a Unique Model to Test CD22-Targeted Therapies (2018) Wagner F, Brandl C, Emmerich C, Mackensen A, Nitschke L, Müller F Conference contribution